Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.
|Original language||English (US)|
|Number of pages||5|
|Journal||ONCOLOGY (United States)|
|State||Published - Aug 15 2017|
ASJC Scopus subject areas
- Cancer Research